A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2020-06-24
Target enrollment:
Participant gender:
Summary
This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to
provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2.
Following the identification of a recommended dose and regimen from Part 1, the study entered
Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with
select solid tumors, and to confirm target engagement and downstream pathway impact in
patients with any solid tumor histology.